Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03824938 · ClinicalTrials.gov registry record · Phase 3
Aspirin for Exercise in Multiple Sclerosis (ASPIRE)
A Phase 3 study of Multiple Sclerosis, sponsored by Columbia University.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03824938 is a Phase 3 study of Multiple Sclerosis that has completed, run by Columbia University. The registered enrollment target is 60 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03824938, a Phase 3 study of Multiple Sclerosis, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This study investigates the use of aspirin as an exercise pre-treatment to reduce overheating and exhaustion, which may potentially allow many more people with multiple sclerosis to participate in and benefit from exercise. The design is double-blind, within-subject, with three arms: participants will receive one of three treatments at three separate study visits: aspirin, acetaminophen, and placebo, followed by completion of a maximal exercise test.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Aspirin 650mg Oral Capsule
- DRUG Acetaminophen Tablet 650mg
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2019-04-30 |
| Est. Completion | 2022-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03824938
The ClinicalTrials.gov registry entry for NCT03824938 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (90% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03824938 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03824938 about?
NCT03824938 is a clinical study titled "Aspirin for Exercise in Multiple Sclerosis (ASPIRE)". This study investigates the use of aspirin as an exercise pre-treatment to reduce overheating and exhaustion, which may potentially allow many more people with multiple sclerosis to participate in and benefit from exercise. The design is double-blind, within-subject, with three arms: participants wi...
What is the current status of trial NCT03824938?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2019-04-30. Estimated completion is 2022-02-28.
What conditions does trial NCT03824938 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT03824938?
The interventions under investigation include: Placebo (OTHER), Aspirin 650mg Oral Capsule (DRUG), Acetaminophen Tablet 650mg (DRUG).
Who is sponsoring clinical trial NCT03824938?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03824938 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 3
-
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
RECRUITING · Phase 3
-
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.